Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Regulatory News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: 0.00 (0.00%)
Spread: 0.20 (12.50%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
CIZ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Feb 2022 14:29

RNS Number : 7875A
Cizzle Biotechnology Holdings PLC
04 February 2022
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Cizzle Biotechnology Holdings PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

change in percentage of voting rights arising upon a new issue of shares by the issuer

3. Full name of person(s) subject to thenotification obligation: iii

Enterprise Ventures Limited

4. Full name of shareholder(s) (if different from 3.):iv

Finance Yorkshire Seedcorn Fund LP

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

4th February 2022

6. Date on which issuer notified:

4th February 2022

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct xi

Indirecti

Direct

Indirect

CIZ

22,937,410

22,937,410

7,437,410

7,437,410

Nil

2.93

Nil

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

None

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

None

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,437,410

2.93%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Enterprise Ventures Limited

15. Contact telephone number:

 01772 270 570

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSUSRUNUURAR
Date   Source Headline
22nd Jun 20217:00 amRNSMOU for the Development of a Companion Diagnostic
7th Jun 20214:45 pmRNSHolding(s) in Company
7th Jun 20217:00 amRNSNotice of AGM
27th May 20218:48 amRNSChange of Company Name
26th May 20214:41 pmRNSSecond Price Monitoring Extn
26th May 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSResults for the year ended 31 December 2020
17th May 20212:06 pmRNSSecond Price Monitoring Extn
17th May 20212:00 pmRNSPrice Monitoring Extension
17th May 202111:06 amRNSSecond Price Monitoring Extn
17th May 202111:00 amRNSPrice Monitoring Extension
14th May 202110:50 amEQSHardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detection of lung cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.